SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid discussions around potential trade deals with China, particularly regarding access to NVIDIA's Blackwell chips. The community is weighing the implications of these discussions, with some anticipating a positive catalyst and others expressing skepticism about the outcomes. NVIDIA recently achieved a $5 trillion market cap, fueling debates about its valuation and future growth prospects within the AI sector.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to the company's earnings report, which included a significant one-time tax charge and forecasts of increased capital expenditures for AI development. The community is debating whether this decline presents a buying opportunity or signals concerns about future profitability and spending discipline. Some believe the market is overreacting to a non-recurring event, while others worry about the long-term implications of Meta's aggressive AI investments.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid discussions surrounding its recent earnings report and forward guidance, with some investors expressing concern about increased spending on AI and its impact on profitability.  Community talking points include the company's Azure cloud growth, its stake in OpenAI, and reactions to the Trump-Xi meeting. The stock's movement is also being discussed in the context of broader market trends and the performance of other tech giants.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as it approaches all-time highs, fueled by its AI narrative and a recent partnership with NVIDIA, leading to speculation about a potential stock split. Community members are debating the company's valuation and earnings potential, with some anticipating a continued surge while others foresee a pullback. The stock's momentum and strong retail interest have created a battleground between bulls and bears as earnings approach.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending amid discussions of its recent $900M convertible note offering and its implications for dilution and growth, with community members debating the bullish and bearish interpretations of the financing structure. Bullish sentiment highlights the potential for expansion in AI and data centers, while bears focus on the risk of short-term price decline. The conversation also includes speculation around potential partnerships with major players like Google.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors anticipate earnings, with community members discussing potential upgrades and a possible run to $300, fueled by AI, cloud, and advertising services growth. The stock is also benefiting from a lifted DOJ overhang and renewed interest from analysts, with some highlighting its relative undervaluation compared to peers. Additionally, a partnership with NextEra Energy to power AI data centers with nuclear energy is driving positive sentiment.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to after-hours momentum and a low float, sparking community interest in a potential short squeeze. Discussions revolve around its potential to reach higher price levels, with some comparing it to other recent high-flying stocks. However, caution is advised as some traders are calling it a pump and dump scheme.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending downwards after a significant earnings miss and slashed guidance, prompting analyst downgrades and heavy discussion of potential corporate fraud. The community is debating whether the steep drop represents a buying opportunity or a sign of deeper issues, with some pointing to management changes and oversold conditions as potential catalysts for a rebound. Discussions also involve the company's long-term debt and a potential shift to the NASDAQ.

Alphabet Inc - Ordinary Shares - Class C

Recent reports of Google's Q3 earnings exceeding expectations, along with growth in its AI and cloud services, have generated significant buzz around $GOOG. Community members are discussing the potential for the stock to reach new heights, fueled by optimism around Google's advertising, AI strategy, and cloud computing.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust Series 1 (QQQ) is trending amid discussions around potential trade deal implications after recent communications between global leaders. The market is analyzing the potential impacts of these discussions on sectors heavily represented in the fund, particularly technology. Community sentiment appears cautiously optimistic, yet acknowledges that previous similar announcements have not led to substantial long-term gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape Next-Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire VANCOUVER, BC, Oct. 15, 2025 USA News Group...

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

Shares of GT Biopharma had their best trading day in more than nine months after the company shared encouraging progress from its ongoing Phase 1 trial of GTB-3650, an experimental treatment for patients with relapsed or refractory CD33-positive blood cancers.The stock jumped 43.7% to $1.08 at Wednesday’s close, before slipping 10.5% in after-hours trading.The clinical-stage biotech company said enrollment in the study’s dose-escalation groups is progressing smoothly and remains “well on track.” Both patients in Cohort 3 have now begun treatment, with no signs of dose-limiting toxicities or tolerability issues so far.&nbsp;The company added that the first patient in Cohort 3 has shown “promising evidence of immune activation,” matching the levels of activity seen in patients from the two earlier, lower-dose groups.GT Biopharma's trial will evaluate the safety, pharmacokinetics/pharmacodynamics of GTB-3650, and evidence of immune activation. GTB-3650 will use the company's TriKE platform to recruit natural killer (NK) cells to fight cancer.The Phase 1 study can enroll up to 14 patients, with two people in each of seven planned dosing groups. The lowest dose starts at 1.25 micrograms per kilogram per day and could go up to 100 micrograms per kilogram per day in the highest group. Each patient will take the drug in two-week treatment cycles, with two weeks on therapy followed by two weeks off, for as long as four months if they continue to show signs of clinical benefit.If Cohort 3 is dosed without any problems, GT Biopharma anticipates dosing the first patient in Cohort 4 by the end of 2025. The dose level can be increased further if warranted. The company expects to provide an update on additional data by the end of 2025 and in the first quarter of 2026 as it moves to the higher dose levels in the trial that may yield more robust therapeutic effects.On Stocktwits, retail sentiment for GT Biopharma was ‘extremely bullish’ amid a 2,933% surge in 24-hour message volume.One user said that GT Biopharma shares appeared to be gaining strong upward momentum and could move toward double-digit levels.&nbsp;<stembedurl>https://stocktwits.com/Illbeyourhuckleberree/message/631516421</stembedurl>Another user commented that the company’s cancer therapy showed significant promise, with the potential for substantial long-term returns.<stembedurl>https://stocktwits.com/Djdanny/message/631566315</stembedurl><a href="https://stocktwits.com/symbol/GTBP">GT Biopharma’s stock</a> has declined 65% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

GT Biopharma’s stock (GTBP) has declined 65% so far in 2025. (Photo credit: Getty Images)

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

The biotech firm reported smooth progress in its Phase 1 trial of GTB-3650, with no safety issues and early signs of immune activation in the latest dosing group. 

Equity

Shares of GT Biopharma, Inc. surged more than 21% on Tuesday before slipping after-hours as investors reacted to the company's unexpected shift in its financing strategy.&nbsp;The announcement sent 24-hour message volume on Stocktwits skyrocketing by 18,700%, marking the highest spike among biotech stocks, with trading volume more than doubling from its daily average.The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.&nbsp;The filing had not yet been declared effective, and no securities had been sold under the proposed offering.&nbsp;Instead, GT Biopharma opted for a direct warrant exercise agreement, securing immediate funds while offering new unregistered warrants to investors.Under the new arrangement, the company entered into definitive agreements to exercise existing warrants to purchase 302,069 shares of common stock, with an exercise price of $4.35 per share.&nbsp;The move is expected to generate approximately $700,000 in gross proceeds before deducting placement agent fees and offering expenses.The offering is anticipated to close by Thursday, with proceeds earmarked for working capital and general corporate purposes.On Stocktwits, retail investors' reactions were mostly positive to the company's financing shift.&nbsp;One user described the move as "going in the right direction."&nbsp;<stembedurl>https://stocktwits.com/Rassy40/message/605686808</stembedurl>Another pointed out that short sellers had expected dilution due to the S-1 registration, but they may now be forced to cover with the offering canceled.&nbsp;<stembedurl>https://stocktwits.com/Annet_why_net/message/605691704</stembedurl>However, some traders indicated they were still waiting for a more attractive entry point.Short interest on GTBP shares has jumped from 0.6% at the start of the year to 8.8% at the end of last week, per Koyfin data.Beyond the financing development, Roth MKM remains optimistic about GT Biopharma's clinical pipeline.&nbsp;The research firm expects the company to release initial data later this year from its Phase 1 trial evaluating GTB-3650, its therapy targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.GT Biopharma ended 2024 with approximately $4 million in cash, which Roth MKM estimates is sufficient to fund operations into the second quarter of this year.&nbsp;The research firm maintained a 'Buy' rating on the stock, with an $11 price target, implying a potential fivefold increase from current levels.The company's stock has lost more than 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.

Recap: GT Biopharma Q4 Earnings

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...

GT Biopharma trading halted, news pending

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GT Biopharma announces 1-for-30 reverse stock split

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.5971
Prev Close	$0.6668
Open	$0.6671
Dividend Yield	0.00%
50-Day Moving Average	$0.8054
Beta	0.87
Avg. Volume	625,755.52
PE Ratio	-0.15

52-Week High	$4.10
52-Week Low	$0.55
Market Capitalization	$2.12M
EPS (Annual)	-$6.94
Price to Book	0.68
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GTBP News

GTBPGT Biopharma Inc